Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 14/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.56 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | DRD3 | P35462 | 4/20 | 0.55 |
| ▸ | DRD4 | P21917 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arbutamine SCHEMBL3699485 | 1.00 | ADRB2 (0.61) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Arbutamine SCHEMBL29929016 | 1.00 | ADRB2 (0.61) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Arbutamine SCHEMBL20769823 | 1.00 | ADRB2 (0.61) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Arbutamine SCHEMBL521645 | 1.00 | ADRB2 (0.61) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Arbutamine SCHEMBL7295080 | 0.99 | ADRB2 (0.60) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Arbutamine SCHEMBL40757 | 0.99 | ADRB2 (0.60) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Arbutamine SCHEMBL4327619 | 0.97 | ADRB2 (0.59) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Arbutamine SCHEMBL7870502 | 0.94 | ADRB2 (0.58) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Hexoprenaline SCHEMBL121449 | 0.85 | ADRB2 (0.72) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Hexoprenaline SCHEMBL32668781 | 0.85 | ADRB2 (0.72) | ADRB2ADRB1ADRB3DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025265094-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | RDE PHARMA | 2022-07-21 | — | — | US | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | PAH, BPGM, TPMT | ADRB2 1682/4885ADRB1 1330/4885ADRB3 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.